Study
EORTC-2418-GUCG-STARBURST 1
Multimodal strategies to define Clinical Response to neoadjuvant therapy in Muscle-invasive Bladder Cancer (Starburst-1)
Trial Status
Regulatory in Process
Dates
Data management at EORTC
Yes
Design
Cohort
Not randomized / N.A.
Not randomized / N.A.
Targeted Sample size
EORTC Groups: 240 - All Groups: 240
Study Staff
- Alexandra Masson Lecomte (Study Coordinator), APHP Nord - Univ De Paris Cite - Hop. Saint Louis, Paris
- Yves Allory (Study Co-Coordinator), Institut Curie - l' Hopital de St Cloud, Saint-Cloud
- Thierry Nicolas Boellaard (Study Co-Coordinator), The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam
- Lars Dyrskjot (Study Co-Coordinator), Region Midtjylland - Aarhus University Hospital-Skejby, Aarhus
- Valeria Panebianco (Study Co-Coordinator), Azienda ospedaliero Univ Policlinico Umberto I, Roma
- Guillaume Grisay (Y-ECI Coordinator), CHU Helora Pole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul
- Tina Verschuere (Project Manager), EORTC Headquarters, Brussels
- Bert Dhondt (Clinical Research Physician), EORTC Headquarters, Brussels
- Beatrice Fournier (Medical representative), EORTC Headquarters, Brussels
- Cedric Mallien (TR Scientist), EORTC Headquarters, Brussels
- Florence Dujardin (Junior Clinical Operations Manager), EORTC Headquarters, Brussels
- Camila Matiollo (Data Manager), EORTC Headquarters, Brussels
- Axelle Nzokirantevye (Imaging DM), EORTC Headquarters, Brussels
- Jelle Stans (Regulatory Affairs Manager), EORTC Headquarters, Brussels
- Anja Mestnik (Junior RAM), EORTC Headquarters, Brussels
- Lucy Sepulveda (Junior RAM), EORTC Headquarters, Brussels
- Shyamala Rajarajacholan (Clinical Operations Assistant), EORTC Headquarters, Brussels
- Olga Basova (Senior Statistician), EORTC Headquarters, Brussels
Type of cancer
- Bladder
Participating groups
- EORTC Genito-Urinary Cancers Group
Centers to be activated
- APHP Centre - Univ de Paris Cite - Hopital Europeen Georges Pompidou (PARIS, France)
- APHP Sorbonne Univ - Hopital la Pitie-Salpetriere (Paris, France)
- AZ Groeninge Kortrijk - Campus Kennedylaan (Kortrijk, Belgium)
- AZ Maria Middelares (Gent, Belgium)
- Azienda ospedaliero Univ Policlinico Umberto I (Roma, Italy)
- CHU Helora Pole Hospitalier Jolimont - Hopital Jolimont (Haine-Saint-Paul, Belgium)
- CHU de Lille - Hopital Huriez (Lille, France)
- Clinique La Croix Du Sud (Quint-Fonsegrives, France)
- Clinique Pasteur-Toulouse (Toulouse, France)
- Cliniques Universitaires Saint-Luc (Brussels, Belgium)
- IRCCS - Fondazione Istituto Nazionale dei Tumori (Milano, Italy)
- IRCCS Ospedale San Raffaele (Milano, Italy)
- IRCCS-Regina Elena National Cancer Center (Roma, Italy)
- Institut Bergonie (Bordeaux, France)
- Institut Jules Bordet (Anderlecht, Belgium)
- Institut Paoli-Calmettes (Marseille, France)
- Institut de Cancerologie de Lorraine (Vandoeuvre les Nancy, France)
- The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, Netherlands)
- Vilnius University Hospital Santaras Clinics Branch-National Cancer Center (Vilnius, Lithuania)
Protocol summary
NCT number
NCT02834884
Study
EORTC-2418-GUCG-STARBURST 1
Multimodal strategies to define Clinical Response to neoadjuvant therapy in Muscle-invasive Bladder Cancer (Starburst-1)
Linked Studies
EORTC-1553-SPECTA
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access